Diabetes Assays - Medical Devices Pipeline Assessment, 2019

Published by Global Data on 14th November 2019 | Ref: 1464189 | This Product Is In Stock

$4000 | Single User
$8000 | Site License
$12000 | Enterprise License
$4000 | Single User
$8000 | Site License
$12000 | Enterprise License

Introduction

Diabetes Assays - Medical Devices Pipeline Assessment, 2019

Summary

GlobalData's Medical Devices sector report, “Diabetes Assays - Medical Devices Pipeline Assessment, 2019" provides an overview of Diabetes Assays currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Diabetes Assays pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

- Extensive coverage of the Diabetes Assays under development

- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities

- The report reviews the major players involved in the development of Diabetes Assays and list all their pipeline projects

- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage

- The report provides key clinical trial data of ongoing trials specific to pipeline products

- Recent developments in the segment / industry

Reasons to buy

The report enables you to -

- Formulate significant competitor information, analysis, and insights to improve R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of Diabetes Assays under development

- Develop market-entry and market expansion strategies

- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline

- In-depth analysis of the product’s current stage of development, territory and estimated launch date

Table of Contents

Table of Contents

1.1 List of Tables 5

1.2 List of Figures 7

2 Introduction 9

2.1 Diabetes Assays Overview 9

3 Products under Development 10

3.1 Diabetes Assays - Pipeline Products by Stage of Development 10

3.2 Diabetes Assays - Pipeline Products by Segment 11

3.3 Diabetes Assays - Pipeline Products by Territory 12

3.4 Diabetes Assays - Pipeline Products by Regulatory Path 13

3.5 Diabetes Assays - Pipeline Products by Estimated Approval Date 14

4 Diabetes Assays - Pipeline Products under Development by Companies 15

4.1 Diabetes Assays Companies - Pipeline Products by Stage of Development 15

4.2 Diabetes Assays - Pipeline Products by Stage of Development 17

5 Diabetes Assays Companies and Product Overview 19

5.1 Abcodia Ltd Company Overview 19

5.2 Adaptive Biotechnologies Corp Company Overview 20

5.3 Alfa Wassermann Inc Company Overview 21

5.4 AmideBio LLC Company Overview 22

5.5 Aura Biotechnologies Pvt Ltd Company Overview 23

5.6 Beckman Coulter Inc Company Overview 25

5.7 Biocrates Life Sciences AG Company Overview 29

5.8 Caprion Biosciences Inc Company Overview 31

5.9 DaekiTech Company Overview 33

5.10 Drexel University Company Overview 34

5.11 ELITechGroup Inc Company Overview 35

5.12 Enable Biosciences Inc Company Overview 37

5.13 FibroStatin SL Company Overview 39

5.14 Fujirebio Diagnostics Inc Company Overview 40

5.15 Genalyte Inc Company Overview 41

5.16 Genesis Detection Systems, Inc. Company Overview 42

5.17 Helmholtz Centre for Infection Research Company Overview 43

5.18 Hemex Health Inc Company Overview 44

5.19 ImmusanT Inc Company Overview 45

5.20 IntraMed Diagnostics, LLC Company Overview 46

5.21 Janssen Diagnostics LLC Company Overview 47

5.22 Johns Hopkins University Company Overview 48

5.23 Mellitus LLC Company Overview 49

5.24 Numares AG Company Overview 50

5.25 Ortho-Clinical Diagnostics Inc Company Overview 51

5.26 Peri Rx Inc Company Overview 53

5.27 PortaScience Inc Company Overview 54

5.28 Protagen AG Company Overview 55

5.29 Queen Mary University of London Company Overview 56

5.30 QuickCheck Health Inc Company Overview 57

5.31 Shenzhen Mindray Bio-Medical Electronics Co Ltd Company Overview 58

5.32 Singulex Inc Company Overview 60

5.33 SomaLogic Inc Company Overview 61

5.34 The Forsyth Institute Company Overview 62

5.35 University of Canterbury Company Overview 63

5.36 University of Colorado Company Overview 64

5.37 University of Florida Company Overview 65

5.38 University of Oxford Company Overview 66

5.39 University of South Florida Company Overview 67

5.40 Xhale Inc Company Overview 68

5.41 Yaathum Biotech Pvt Ltd Company Overview 69

6 Diabetes Assays- Recent Developments 70

6.1 Aug 30, 2019: Discovery paves the way for earlier detection of type 1 diabetes 70

6.2 Jul 30, 2019: Proteomics International : Quarterly business activities update 71

6.3 Jul 25, 2019: EKF to highlight Lucica Glycated Albumin-L assay for diabetes patient monitoring at AACC 2019 75

6.4 Jul 22, 2019: Study finds common blood tests could predict diabetes 75

6.5 Jun 05, 2019: Hamilton And Enable Biosciences Team Up to Automate Ultra-Sensitive Antibody Detection Assay Platform 76

6.6 Jun 01, 2019: Greg Milosevich appointed President of Beckman Coulter Life Sciences 77

6.7 May 14, 2019: Siemens Healthineers Hemoglobin A1c test for diagnosing and monitoring Diabetes now available on the Atellica Solution 77

6.8 May 14, 2019: Ortho Clinical Diagnostics to host 4th Annual Hospital C-Suite Summit in Singapore 78

6.9 Apr 24, 2019: Proteomics International Laboratories: Quarterly business update for the year 2019 78

6.10 Apr 01, 2019: Mologic expands US and UK operations 81

7 Appendix 90

7.1 Methodology 90

7.2 About GlobalData 93

7.3 Contact Us 93

7.4 Disclaimer 93

Additional Details

Publisher

Global Data

Publisher Information

Reference

1464189 | GDME0819EPD

Number of Pages

93

Report Format

PDF

Related Reports

Title
Date Published
Price From
Link

Published by imarc - International Market Analysis Research and Consulting Group
15-02-2017

$1,200 USD

Published by imarc - International Market Analysis Research and Consulting Group
15-02-2017

$1,200 USD

This report is published by Global Data

Global Data deliver comprehensive, detailed market intelligence that provides a definitive picture of the markets they serve. Their data is complete, detailed, global and completely cross-country comparable.

With different types of data other providers don’t provide, our clients can access a variety of tools that add context to our core data including innovation tracking, sentiment analysis, price monitoring, M&A tracking, competitor intelligence, and city-level intelligence.

Download Free Report Summary PDF

Diabetes Assays - Medical Devices Pipeline Assessment, 2019 | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.